{'fraction_non_alphanumeric': 0.026170798898071626, 'fraction_numerical': 0.01652892561983471, 'mean_word_length': 5.54954954954955, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506.

The novel immunosuppressive drug FK-506 inhibits both cell-mediated and humoral immunity in vivo and suppresses T-lymphocyte activation at nanamolar concentrations in vitro. We report here that FK-506 also inhibits the in vitro proliferation of murine B lymphocytes induced by goat antimouse IgM (GaMIgM), although it does not affect the induction of proliferation by bacterial lipopolysaccharide (LPS). The action of FK-506 on B-lymphocyte proliferation thus resembles that of cyclosporin A, further strengthening the correlation between the action of the two immunosuppressive drugs previously reported for T-lymphocyte activation.